NCT05285345 Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
| NCT ID | NCT05285345 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Bronchopulmonary Dysplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-09-27 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-09-27 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers have worked to create consensus recommendations among national efforts to help with the transition and coordination of care for preterm infants with lung disease around discharge from the neonatal intensive care unit to home. This study looks to evaluate implementation of the recommendations at Boston Children's Hospital and referring NICU's (Beth Israel Deaconess Medical Center and Brigham and Women's Hospital). Specifically, the research team will be looking at follow-up rates, healthcare utilization, and parental satisfaction/feedback with implementation of these guidelines.
Eligibility Criteria
Inclusion Criteria: * Preterm infants born \<32 weeks with at least mild BPD, defined as 28 days of respiratory support after birth. * Efforts will be made to include a mix of infants with mild, moderate, and severe BPD, including infants discharged on oxygen. Exclusion Criteria: * Discharge to a location other than home. * Infants with other congenital disease (cardiac, genetic, neurological) thought to contribute significantly to their respiratory disease.
Contact & Investigator
Jonathan Levin, MD
PRINCIPAL INVESTIGATOR
Boston Children's Hospital
Frequently Asked Questions
Who can join the NCT05285345 clinical trial?
This trial is open to participants of all sexes, aged 0 Days or older, up to 1 Year, studying Bronchopulmonary Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05285345 currently recruiting?
Yes, NCT05285345 is actively recruiting participants. Contact the research team at jonathan.levin@childrens.harvard.edu for enrollment information.
Where is the NCT05285345 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05285345 clinical trial?
NCT05285345 is sponsored by Boston Children's Hospital. The principal investigator is Jonathan Levin, MD at Boston Children's Hospital. The trial plans to enroll 50 participants.